Liquid Chromatography Mass Spectrometry (LCMS) Market Gas Gained Tremendous Demand In The Recent Years On The Account Of Expanding Healthcare Industry
Liquid chromatography mass spectrometry (LCMS) market has become a common method with the evolution of Electrospray Ionization (ESI) giving a robust and simple interface to perform analysis of proteins, DNA/RNA, and other substances. It can also be employed to identify analytes in the solid phase without the need for additional digestion. The use of tandem mass spectrometry and equilibrium independent chromatography methods allows for accurate measurements of amounts and concentrations of hundreds of thousands of single particles and thousands of molecular clusters. It has enabled the detection of novel drugs, regulated substances, quality indicators in food and chemical databases, and produced a reliable quantitative analysis of water and human tissue samples.
The
use of liquid chromatography mass spectrometry (LCMS) market is not limited to
the pharmaceutical or industrial environment, as it is also widely used in the
medical field for the diagnosis and treatment of disease and medical conditions
including diabetes, inflammatory bowel diseases, Parkinson's disease, eye
disorders, sinusitis, throat problems, cancer, and acne.
Growing
investment in the research and development activities across medical industry
is primarily fueling the growth of the liquid chromatography mass spectrometry (LCMS)
market. The increasing focus of key manufacturers on introducing an innovative
product in order to cater to rising demand is again projected to foster the
growth of the market. For instance, in January 2019, Waters introduced the
BioAccord System, a new, purposefully designed liquid chromatography mass
spectrometry (LCMS) system that is expected to expand access to high-resolution
time-of-flight mass spectrometry capabilities to more scientists. The new
system provides the advantage of moving routine monitoring out of centralized
MS labs, allowing more scientists to use it.
On
the other hand, the high cost associated with the liquid chromatography-mass
spectrometry systems is projected to hinder the growth of the market. Thermo
Fisher Partners with Newomics, Evosep, Biognosys for liquid chromatography mass
spectrometry (LCMS) applications, to develop and optimize new microflow LCMS
workflows for the validation of disease biomarkers.
Key Developments:
1. In January 2021, Protein Metrics
and MOBILion Systems announce their strategic partnership to provide data
analysis modules for Protein Metrics’ Byos software suite that works
exclusively with MOBILion’s High-Resolution Ion Mobility (HRIM) Mass
Spectrometry (MS) System
2. In January 2021, SCIEX has
acquired Intabio, a privately held company and the developer of the Blaze™
System for biotherapeutic analysis and quality assessment. Blaze enables the
direct coupling of imaged cIEF charge variant analysis with high-resolution
mass spectrometry to detect intact proteins.
Comments
Post a Comment